Advertisement

Topics

Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

08:00 EDT 14 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced that it has regained compliance with the mini...

Other Sources for this Article

Investor Contact:
IRTH Communications
Robert Haag, 800-439-1433
TENX@irthcommunications.com

NEXT ARTICLE

More From BioPortfolio on "Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...